Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,730,109
  • Shares Outstanding, K 146,443
  • Annual Sales, $ 0 K
  • Annual Income, $ -197,560 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.16
Trade IOVA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.46
  • Number of Estimates 7
  • High Estimate -0.42
  • Low Estimate -0.50
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -15.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.23 +16.61%
on 09/04/20
36.93 -10.86%
on 09/16/20
+1.24 (+3.91%)
since 08/28/20
3-Month
26.75 +23.07%
on 07/24/20
36.93 -10.86%
on 09/16/20
+5.47 (+19.93%)
since 06/30/20
52-Week
17.78 +85.15%
on 10/10/19
41.49 -20.66%
on 05/26/20
+14.72 (+80.88%)
since 09/30/19

Most Recent Stories

More News
Iovance Biotherapeutics (IOVA) Down 1.6% Since Last Earnings Report: Can It Rebound?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IOVA : 32.92 (+1.92%)
Iovance (IOVA) Q2 Earnings Beat Estimates, Pipeline in Focus

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

MRK : 82.95 (+1.28%)
EBS : 103.33 (-0.97%)
HZNP : 77.68 (-0.61%)
IOVA : 32.92 (+1.92%)
Iovance Biotherapeutics to Present at BTIG Biotechnology Conference 2020

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the BTIG Biotechnology...

IOVA : 32.92 (+1.92%)
Iovance Biotherapeutics Reports Second Quarter 2020 Financial Results and Provides a Corporate Update

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL and peripheral-blood lymphocyte,...

IOVA : 32.92 (+1.92%)
Avid Bioservices Selected By Iovance Biotherapeutics to Lead Process Development Through CGMP Manufacturing of Novel IL-2 Analog, IOV-3001

Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development...

CDMO : 7.62 (-0.91%)
CDMOP : 27.00 (+0.47%)
IOVA : 32.92 (+1.92%)
Iovance Biotherapeutics to Present at Upcoming June Conferences

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company plans to present at the following...

IOVA : 32.92 (+1.92%)
DLA Piper advises Iovance Biotherapeutics in its US$604 million common stock offering

, /PRNewswire/ -- DLA Piper represented Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood...

IOVA : 32.92 (+1.92%)
Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IOVA : 32.92 (+1.92%)
Iovance Biotherapeutics, Inc. Announces Closing of $603.7 Million Common Stock Public Offering

Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) ("Iovance" or "Company"), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood...

IOVA : 32.92 (+1.92%)
Iovance Biotherapeutics (IOVA) Upgraded to Buy: Here's What You Should Know

Iovance Biotherapeutics (IOVA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

IOVA : 32.92 (+1.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Iovance Biotherapeutics, Inc. is a biopharmaceutical company. It focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient's own immune system to eradicate cancer cells. Iovance Biotherapeutics Inc., formerly known as Lion Biotechnologies...

See More

Key Turning Points

2nd Resistance Point 33.97
1st Resistance Point 33.45
Last Price 32.92
1st Support Level 32.33
2nd Support Level 31.73

See More

52-Week High 41.49
Last Price 32.92
Fibonacci 61.8% 32.43
Fibonacci 50% 29.64
Fibonacci 38.2% 26.84
52-Week Low 17.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar